From your link:

And analysts quickly began to fret over signs of elevated liver enzymes in some patients taking the drug--a classic red flag in the development world. None of the patients in the placebo arm had elevated levels of liver enzymes while investigators recorded spikes in the enzyme levels of eight people in the 200-mg drug arm and seven patients in the 300-mg arm. There was no evidence, however, of liver damage.

On the plus side, researchers reported that the highest dose did deliver a statistically significant 8.3 percent jump in 'good' HDL levels. But coming right on the heels of anacetrapib's data, reflecting a 138 percent leap in HDL levels after 24 weeks of dosing, Resverlogix's program suffered from some quick comparisons.

Question:

1) Has the elevated liver enzyme problem been resolved,..?

Thanks!